53BP1 mediates sensitivity to chemotherapy and is associated with poor clinical outcomes in high-grade serous ovarian cancer

Michael Skulimowski(Centre Hospitalier de l’Université de Montréal), Françis Rodier(Institute for Research in Immunology and Cancer)
bioRxiv (Cold Spring Harbor Laboratory)
October 3, 2023
Cited by 0


Related Papers